An investment firm headquartered in China invests in both fund-of-funds and direct equity opportunities. Life sciences and healthcare represent one of its primary focus areas, though the firm maintains a multi-sector approach. Its investment sweet spot begins at the pre-A stage and extends through to pre-IPO. While the firm primarily targets opportunities within China, it is open to global companies, particularly those seeking a soft landing in China or with a strong China angle. The firm is flexible on deal structure and is open to both leading investments and co-investments.
Within the healthcare and life sciences sector, the firm is especially interested in biotech therapeutics and medtech. On the therapeutics side, it is open to a range of modalities (excluding mRNA) and indications, with particular interest in areas such as central nervous system (CNS) disorders and oncology. On the medical device side, the firm prioritizes innovative technologies, including invasive solutions, imaging platforms, and brain-computer interfaces. It does not invest in non-innovative categories such as consumables.
The firm does not maintain strict requirements regarding the background of founding teams, though it has a strong preference for companies that are interested in expanding into Shanghai or the broader Chinese market.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment